Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fiebig

Showing results (111-120 of 192) with videos related to

Pageof 20
Sort By:
Journal of Natural Products|September 25, 2007
Julichrome Q6 glucuronide, a monomeric subunit of the julimycin B-I complex from a terrestrial Streptomyces spKhaled A Shaaban, Mohamed Shaaban, Iris Grün-Wollny, et al.
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1985
Comparison of different markers on blood lymphocytes of chronic lymphocytic leukemiaD Götze, H Fiebig, H W Mansfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1995
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologiesD P Berger, L Herbstritt, W A Dengler, et al.
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Bioorganic & Medicinal Chemistry|March 21, 2006
Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activityPaula C A Rodrigues, Thomas Roth, Heinz H Fiebig, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM GroupsM D'Incalci, M Bonfanti, A Pifferi, et al.
The Journal of Investigative Dermatology|October 1, 1986
Serum-mediated inhibition of the interferon-gamma-induced HLA-DR expression on monocytes in patients with psoriasisH D Volk, I Koyka, S R Goan, et al.
The Journal of Allergy and Clinical Immunology|July 10, 1999
Standardization of Alternaria alternata: extraction and quantification of alt a 1 by using an mAb-based 2-site binding assayE Aden, B Weber, J Bossert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer SocietyK Mross, W E Berdel, H H Fiebig, et al.
International Archives of Allergy and Immunology|October 4, 2007
Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapyH Kahlert, R Suck, B Weber, et al.
Pageof 20

Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
Journal of Natural Products|September 25, 2007
Julichrome Q6 glucuronide, a monomeric subunit of the julimycin B-I complex from a terrestrial Streptomyces spKhaled A Shaaban, Mohamed Shaaban, Iris Grün-Wollny, et al.
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1985
Comparison of different markers on blood lymphocytes of chronic lymphocytic leukemiaD Götze, H Fiebig, H W Mansfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1995
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologiesD P Berger, L Herbstritt, W A Dengler, et al.
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Bioorganic & Medicinal Chemistry|March 21, 2006
Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activityPaula C A Rodrigues, Thomas Roth, Heinz H Fiebig, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM GroupsM D'Incalci, M Bonfanti, A Pifferi, et al.
The Journal of Investigative Dermatology|October 1, 1986
Serum-mediated inhibition of the interferon-gamma-induced HLA-DR expression on monocytes in patients with psoriasisH D Volk, I Koyka, S R Goan, et al.
The Journal of Allergy and Clinical Immunology|July 10, 1999
Standardization of Alternaria alternata: extraction and quantification of alt a 1 by using an mAb-based 2-site binding assayE Aden, B Weber, J Bossert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer SocietyK Mross, W E Berdel, H H Fiebig, et al.
International Archives of Allergy and Immunology|October 4, 2007
Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapyH Kahlert, R Suck, B Weber, et al.
Pageof 20